Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at…
Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to…
Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out…
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…